Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

Boehringer Inks Deal with Xencor for Mab Technology

  • Xencor reported a collaboration with Boehringer Ingelheim to optimize therapeutic Mabs with improved clinical performance. Boehringer Ingelheim will apply Xencor’s XmAb™ technology platform, including Fc domains, to maximize the efficacy of its antibody drug candidates against selected targets of interest.

    Xencor says its XmAb Fc domains are designed to enhance the therapeutic properties of antibodies, including sustained half-life, increased structural stability, and greater potency.

    Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional license fees, milestones, and a royalty payment on any products commercialized by Boehringer Ingelheim that incorporate its technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »